PAXLOVID
Copyright infringement not intended.
Context
- Pfizer announced trial results for its investigational Covid-19 oral antiviral candidate, Paxlovid, saying it significantly reduced hospitalisation and death.-why-is-google-doodle-celebrating-her-biceived ‘heaviest rainfall’ since 2015.
About
- It is an investigational SARS-CoV-2 “protease inhibitor antiviral therapy”.
- It inhibits viral replication at proteolysis, a stage that occurs before viral replication.
- It is “designed to be administered orally so that it can be prescribed at the first sign of infection or at first awareness of an exposure, potentially helping patients avoid severe illness.”
- Pfizer said it has entered into advance purchase agreements with “multiple countries and is in negotiations with several others”.